Crystallics has been at the forefront of pre-formulation and solid state research for over a decade. Initially the company operated under the name of Avantium Pharma, and in 2011, a management buy-out created Crystallics. Avantium Pharma was a subsidiary of Avantium Holding, a company founded in February 2000 as a spin-off from Shell. A unique consortium of strategic shareholders including Pfizer, GSK, Eastman Chemical, WR Grace and Akzo Nobel joined as strategic partners and invested in Avantium. The company focused on high-throughput experimentation with applications across a range of industries and created one of the most advanced chemical laboratories in the world. During the first decade of this century, Crystallics has served over 90% of the global top 20 pharmaceutical companies and 100’s of bio-technology companies.